Published: September 2023
The healthcare sector has been highly proactive in implementing artificial intelligence (AI) technologies, particularly in decision-making and risk assessment processes associated with clinical diagnosis.We analyzed around 130 companies that offer AI in clinical trials services across different regions. In this article, discover 10 AI in clinical trials companies and their capabilities in this industry.
Several studies conducted by pharmaceutical companies and research institutions have demonstrated the potential of AI across disease diagnosis, clinical drug development and patient monitoring. In fact, certain AI-based algorithms are known to outperform radiologists at detecting malignant tumors and are capable of guiding researchers to construct cohorts for clinical trials. It is estimated that the application of AI can save over USD 350 million annually in operations associated with healthcare, including drug discovery, manufacturing, marketing, diagnosis and treatment and clinical trials.1
Over the years, pharmaceutical R&D expenditure has increased substantially, however, the approval rate has not increased considerably. Developing a successful drug typically takes 10-15 years and costs around USD 1 billion, but despite this significant investment, 90% of drug candidates fail in clinical trials. Major reasons for the failure are poor data management, noncompliance with regulations, and failure to meet primary and secondary endpoints. In addition, patient recruitment delays and non-adherence to treatment also hinder the progress of clinical trials. Emerging technologies, such as AI, cloud computing, and big data analytics, are being explored to transform clinical research. Further, digital technologies, such as mobile sensors and virtual platforms, make it easier to collect detailed patient data and design better trials. Moreover, AI and advanced data analytics enable efficient identification of promising subjects and risk-based monitoring of trial performance in real-time.
Roots Analysis has conducted an exhaustive study on AI in Clinical Trials Market featuring the current market landscape and future opportunity for the service providers involved in offering AI clinical trials services, over a span of 12 years.
The growing demand for accurate and effective AI-based platforms, driven by the benefits of AI in clinical trials and ongoing advancements, is expected to continue in the coming years as biopharmaceutical manufacturers and researchers strive for safe and efficient drug and biologics development.
Below, we have listed (in alphabetical order), the top 10 companies who are transforming clinical research through software / services implementing AI in Clinical Trials.
1. AiCure
2. Antidote Technologies
3. Deep 6 AI
4. Intel
5. IQVIA
6. Medidata
7. Mendel.ai
8. Phesi
9. Saama Technologies
10. Signant Health
Interested in exploring all 125+ AI in Clinical Trials Companies?
This article highlights the top AI in clinical trials companies to watch out for in the pharmaceutical industry. These companies were chosen based on their service portfolio strength (offering more than five applications for AI in clinical trials). It is essential to note that the selection of top players can differ substantially according to the defined criteria(s)
AiCure Has Shown the Benefits of the Use of Artificial Intelligence and Advanced Data Analytics in Clinical Trials to Improve Medication Adherence
 |
AiCure is a US-based, advanced analytics company focused on providing personalized care. The company also works to improve patient engagement in clinical trials by offering real-time patient monitoring using an AI-powered platform. It is worth mentioning that the company has 65 proprietary technologies that are capable of catering to the requirements of clients across 30 countries around the world.
AiCure offers following types of applications related to AI in clinical trials:
Recent Development Related to AI in Clinical Trials: In September 2022, the company launched its clinical site service offerings to reduce risk during the trials and improve work processes. This offering will provide support to clinical trial sites to monitor adherence, technology use and other parameters amongst study participants.
Use Case / Application of AI in Clinical Trials: In January 2023, the company announced the use of its platform in post traumatic stress disorder (PTSD) trial run by Defence Health Agency. The trial will recruit 450 patients and monitor them over a 12 week period using AiCure’s platform.2
Company’s artificial intelligence platform was also used in a randomized controlled trial to evaluate the benefit of platform in increasing medication adherence in stroke survivors. The results for the trial were published in April 2017 in American Heart Association's journal Stroke. Further information related to platforms / technologies, key offerings and potential end users is available in the full report.
 |
Antidote Technologies is a US-based digital health company, which was incorporated as TrialReach. The company’s proprietary technology, named Enterprise Match, involves the use of AI for patient recruitment and engagement. Fundamentally, it is a patient matching platform that connects the appropriate subjects for a clinical study with the concerned trial sponsors. In addition, the firm also provides educational webinars and patient stories in order to enhance patient knowledge and understanding about clinical studies.
Antidote Technologies offers following types of applications related to AI in clinical trials:
Recent Developments Related to AI in Clinical Trials: In February 2023, the company entered into a collaboration with XpertPatient.com to enhance clinical trial patient matching. XpertPatient is an educational website for cancer patients and access to Antidote Match platform will be useful for patients to find suitable clinical trials for them.
Use Case / Application of AI in Clinical Trials: Back in 2018, Antidote Technologies helped one pharmaceutical company, which required the registry of approximately 8,000 patients for the purpose of trial design and patient recruitment in its future Alzheimer’s clinical trials. Additionally, they required a patients’ survey follow-up, post the completion of the trial.
In order to meet this requirement Antidote Technologies first developed a pre-screening website to identify eligible patients for the registry. Secondly, Antidote used their proprietary data to reach out to potential patients suffering from early symptoms of Alzheimer’s.3 Further information related to platforms / technologies, key offerings and potential end users is available in the full report.
 |
Deep 6 AI is a US-based data mining company. Its proprietary technology uses AI and natural language processing for mining patient data and generates actionable insights to support patient enrolment in clinical trials. The company’s clientele features pharmaceutical companies, hospitals, consulting physicians and patients. It is worth mentioning that the company claims to enroll patients?three times faster?to its associated clinical sites as compared to other companies offering clinical trial recruitment solutions.
Deep 6 AI offers following types of applications related to AI in clinical trials:
Recent Developments Related to AI in Clinical Trials: In September 2023, the company launched a genomics module to its AI platform that allows clinical trial matching. The enhanced feature will allow precision matching of patients based on their genomic profile, in addition to the clinical profile.
Use Case / Application of AI in Clinical Trials: In August 2023, Texas Tech University Health Sciences Center announced a collaboration with Deep 6 AI to integrate their artificial intelligence platform within the university’s electronic medical record system. The platform will allow the matching of patients with clinical trials to fasten the enrolment.4
In February 2022, Deep 6 AI entered into a collaboration with Carle for the deployment of AI in clinical trials. Further information related to platforms / technologies, key offerings and potential end users is available in the full report.
 |
Intel is the world’s largest PC microprocessor manufacturer and aims to lead innovation in the domain by unleashing the full potential of data to offer best possible solutions for individuals and businesses. Intel works with multiple industries across the globe and is actively using its expertise to accelerate transformation in the healthcare industry. The company has developed an AI-based platform to enable remote patient monitoring and data analysis in clinical trials. In addition, the company is deploying IoT’s and data-smart solutions to identify diseases, personalize treatment and streamline the decision-making.
Intel offers following types of applications related to AI in clinical trials:
Recent Developments Related to AI in Clinical Trials: In April 2018, a leading contract research organization (CRO) ICON announced its collaboration with Intel to use their AI based remote monitoring platform in clinical trials.
Use Case / Application of AI in Clinical Trials: In December 2022, Intel Labs announced the completion of a clinical study, in collaboration with Perelman School of Medicine, using Intel’s AI hardware and software to improve detection of malignant brain tumors. The AI algorithm was trained using 3.7 million images from 6,314 Glioblastoma Multiforme patients and the results showed a 33% improvement in tumor detection using the platform. The company’s Intel Pharma Analytics Platform has also been used by other academic institutes such as Scripps Research Institute, Mount Sinai Hospital and Radbound University. Additionally, the platform has been used by pharmaceutical companies in their clinical trials such as Teva Pharmaceutical’s mobile health trial on Huntington’s Disease and by ICON PLC for a non-interventional clinical trial on respiratory disorders.5 Further information related to platforms / technologies, key offerings and potential end users is available in the full report.
 |
IQVIA, formed through the merger of Quintiles and IMS Health in 2016 is a US-based pharmaceutical company, which offers advanced analytics, clinical research services and technology solutions to the healthcare industry. Additionally, the firm focuses on accelerating the drug development process, enhancing commercial efficacy, maintaining product quality and safety, and improving access and delivery of healthcare. It harnesses the capabilities of IQVIA Connected Intelligence in order to fasten patient identification and enrollment process in clinical trials, eliminate cost-related obstacles and reduce the site burden.
IQVIA offers following types of applications related to AI in clinical trials:
Recent Developments Related to AI in Clinical Trials: In February 2019, IQVIA acquired Linguamatics to incorporate the machine learning and AI within their offerings.
Use Case / Application of AI in Clinical Trials: In November 2022, IQVIA assisted a large biotech company to identify the patients accurately, which are less likely to continue the treatment for multiple sclerosis.
IQVIA used its AI as well as machine learning methods and predicted that over 80% of the patients will discontinue their treatments. This helped the biotech company to develop some strategies to improve the patient adherence.6 Further information related to platforms / technologies, key offerings and potential end users is available in the full report.
 |
Medidata, a US-based software development company, is focused on generating evidence and insights to help academic research institutes as well as pharmaceutical, biotech, medical device and diagnostics companies. Its AI-based trials solution, powered by advanced analytics and AI technology, can provide real-time performance metrics, predictive models and forecasting capabilities to navigate the complexities of the clinical trial landscape and gain a competitive advantage in trial planning and execution.
Medidata offers following types of applications related to AI in clinical trials:
Recent Developments Related to AI in Clinical Trials: In February 2022, Medidata collaborated with PPD, the CRO arm of Thermo Fisher, to optimize clinical trial site selection, trial enrollment and study cycle times using Medidata AI Intelligent Trials’.
In April 2023, Medidata entered into a collaboration with Lambda Therapeutics, an India based CRO, to automate and streamline data management processes for greater clinical trial efficiency. The company will be using Medidata’s Rave EDC, Rave RTSM and Rave Imaging products.
Use Case / Application of AI in Clinical Trials: In August 2022, Medidata AI's Commercial Data Solutions (CDS) assisted a mid-sized biopharmaceutical company to understand the decline in the sales of their launched drug by the prescribers. The team of Medidata Commercial Data Solutions created its advanced machine learning algorithms and identified crucial factors which can influence the prescriber. Moreover, they suggested various solutions to the company, which can increase their sales using their machine learning and advanced analytic tools.7 Further information related to platforms / technologies, key offerings and potential end users is available in the full report.
 |
Mendel.ai is a software developer headquartered in the US. The company's mission is to make actual patient experiences more accessible to everyone by democratizing it. It is dedicated to investing in research and development with the ultimate goal of developing an innovative AI-supported clinical research platform that can organize real-world data and automate clinical trials focused on oncology research. In addition, the company's software aims to address challenges throughout the clinical trial process, from feasibility assessments to post-trial pharmacovigilance.
Mendel.ai offers following types of applications related to AI in clinical trials:
Recent Developments Related to Application of AI in Clinical Trials: In April 2022, Mendel.ai received funding worth USD 40 million from Oak HC/FT and DCM to expand its AI team.
Use Case / Application of AI in Clinical Trials: In April 2023, Mendel.ai changed the method of identifying the right patients for clinical trials for an undisclosed organization. The company was identifying the patients manually, which is expected to take hundred of hours and challenged with inefficiencies. Post using the Mendel’s AI, the company was able to reduce the efforts significantly in the identification of eligible patients.8 Further information related to platforms / technologies, key offerings and potential end users is available in the full report.
 |
Phesi is a US-based company, offering AI-assisted clinical development technology and services to biopharmaceutical companies. It claims to support better clinical trial design, in order to expedite the drug development process. The firm has developed ClinSite, which is an analytical tool that is programmed to expedite patient enrollment and site selection processes. Moreover, the company’s SaaS platform is used to minimize patient burden and speed up the process of conducting patient-focused clinical trials.
Phesi offers following types of applications related to AI in clinical trials:
Recent Developments Related to Application of AI in Clinical Trials: In January 2020, Phesi entered into a collaboration with Sensyne Health to strengthen offerings related to clinical trials.
Use Case / Application of AI in Clinical Trials: In January 2020, OncoSec Medical purchased a license to Phesi’s ClinSite to enable the clinical trial planning for phase 2 and phase 3 trials for cancer immunotherapies in its pipeline.9 Further information related to platforms / technologies, key offerings and potential end users is available in the full report.
 |
Saama Technologies is a US-based, data analytics company, offering a proprietary AI-powered clinical analytics cloud platform. The company has developed Life Science Analytics Cloud (LSAC), an AI-powered data analytics platform that analyzes multiple data systems and data types to offer operation insights, clinical insights and risk-based monitoring. In addition, in February 2022, Saama has introduced an information security program that incorporates "Security by Design" approach to safeguard patient data from the latest threats in an environment of increasing risks.
Saama Technologies offers following types of applications related to AI in clinical trials:
Recent Developments Related to Application of AI in Clinical Trials: In August 2022, Saama Technologies entered into a collaboration with Merck to expand capabilities and accelerate clinical pipeline.
Use Case / Application of AI in Clinical Trials: Saama Technologies helped a hospital organization to understand more about patient experience. The company developed a solution to identify the concerns of patients and develop insights on strategies to help the hospitals improve their services. The Saama Analytics Framework was developed using the big data analytics and natural language processing (NLP).10 Further information related to platforms / technologies, key offerings and potential end users is available in the full report.
 |
Signant Health is a US-based company that specializes in utilizing software, operational proficiency, and extensive therapeutic and scientific expertise to effectively gather, compile and reveal high-quality evidence for clinical studies conducted through traditional, virtual and hybrid trial approaches. Signant's clinical data management solutions leverage advanced AI and cloud-based technologies to empower study teams and data managers by offering powerful tools that simplify the increasingly complex task of organizing, preparing and analyzing clinical data.
Signant Health offers following types of applications related to AI in clinical trials:
Recent Developments Related to Application of AI in Clinical Trials: In November 2020, Signant Health acquired VirTrial to enhance its digital enablement of clinical research sites and evidence generation capabilities.
Use Case / Application of AI in Clinical Trials: During the pandemic, Signant Health helped Pfizer to enroll thousands of patients for its COVID vaccine trial. Signant Health managed the data from more than 40,000 patients using its electronic methodologies. The platform offered was able to execute this study in a short time span.11 Further information related to platforms / technologies, key offerings and potential end users is available in the full report.
The above presentation features ten AI in clinical trials companies selected from a pool of over 125 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
I am Nancy Kapila, an accomplished pharmaceutical consultant with a rich and diverse experience spanning more than 5 years. My educational background includes a Master's degree in Pharmaceutics (M.Pharm) from Panjab University, which has provided me with a solid foundation in understanding the intricate mechanisms of drugs and their interactions within the human body. Throughout my professional journey, I have had the privilege of working with various pharmaceutical companies, leveraging my expertise to provide valuable insights and strategic guidance.
What sets me apart is my unwavering commitment to staying at the forefront of the ever-evolving pharmaceutical landscape. In an industry characterized by rapid advancements and dynamic changes, I make it a priority to remain well-informed about the latest developments, regulatory updates, and emerging trends. This continuous learning not only keeps me well-equipped to navigate the complexities of the field but also enables me to offer innovative solutions that drive client success. One of my core passions lies in harnessing the power of data to uncover actionable insights. I am deeply fascinated by the potential of data analytics and its transformative impact on decision-making. By delving into data, I can identify patterns, trends, and opportunities that might otherwise remain hidden. This enables me to provide clients with evidence-based recommendations that optimize processes, enhance product development, and drive operational efficiency. In addition to my technical skills, I am recognized for my strong interpersonal and communication abilities. Collaborating with cross-functional teams, I facilitate productive discussions that bridge the gap between scientific expertise and business objectives. Whether I'm working on drug development strategies, regulatory compliance, or market analysis, my goal is to provide holistic solutions that not only meet immediate needs but also contribute to long-term growth.
My journey has been marked by a continuous quest for knowledge, an unrelenting passion for data-driven insights, and an unwavering commitment to guiding pharmaceutical companies towards success in an ever-changing world.
Nancy.Kapila@rootsanalysis.com
https://www.linkedin.com/in/nancy-kapila-4336b4129/
Source 1: https://www.healthcaredive.com/news/artificial-intelligence-healthcare-savings-harvard-mckinsey-report/641163/
Source 2: https://www.medicaldevicetechnology.com/view/ptsd-study-uses-precision-medicine-tech-from-aicure
Source 3: https://www.antidote.me/blog/clinical-trial-patient-recruitment-case-study-alzheimers-disease
Source 4: https://www.prnewswire.com/news-releases/texas-tech-university-health-sciences-center-partners-with-deep-6-ai-to-launch-an-ai-program-for-clinical-trials-301885663.html
Source 5: https://www.intel.ca/content/dam/www/public/us/en/documents/solution-briefs/transforming-clinical-trials-with-the-power-of-ai-brief.pdf
Source 6: https://www.iqvia.com/library/case-studies/preventing-early-drug-discontinuation
Source 7: https://www.medidata.com/en/life-science-resources/medidata-blog/optimized-physician-outreach-with-commercial-data-solutions/
Source 8: https://www.mendel.ai/post/how-one-organization-changed-the-way-patients-are-identified-for-clinical-trials-with-ai
Source 9: https://www.businesswire.com/news/home/20200122005086/en/OncoSec-Secures-Phesi-ClinSite%E2%84%A2-License-to-Select-Clinical-Trial-Investigator-Sites
Source 10: https://cdn.featuredcustomers.com/CustomerCaseStudy.document/saama-technologies_regional-hospital-management-organization_45423.pdf
Source 11: https://www.signanthealth.com/company/newsroom/item/fastest-vaccine-covid/
MEDIA CITATIONS
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES
.png)
